Impact of mRNA COVID-19 Vaccines on Blood Pressure in Hypertensive Patients: A Retrospective Observational Study

The COVID-19 pandemic necessitated rapid vaccine development, with mRNA vaccines (Moderna or Pfizer) emerging as frontrunners. While effective, concerns arose regarding their impact on blood pressure (BP), particularly in hypertensive individuals, a population already at increased cardiovascular risk. The study aimed to investigate the effects of mRNA COVID-19 vaccines on BP in hypertensive patients. A retrospective observational study was conducted at the Mrebet Community Health Center. Data from hypertensive patients receiving the second dose of either Moderna or Pfizer vaccine were analyzed. Pre- and post-vaccination BP readings, patient demographics, medication profiles, and hypertension severity were assessed. Statistical analysis was performed to evaluate changes in BP and identify potential associations. The study included 33 hypertensive patients (mean age: 55.2 years, 84.8% female). The majority (84.8%) received the Moderna vaccine. Pre- and post-vaccination BP readings showed a slight increase in systolic BP (133 mmHg to 137 mmHg) and a minor decrease in diastolic BP (85 mmHg to 84 mmHg). Statistical analysis revealed a significant association between vaccination and changes in diastolic BP (p < 0.05), but not systolic BP (p > 0.05). In conclusion, mRNA COVID-19 vaccines may have a modest impact on BP in hypertensive patients, particularly on diastolic BP. The clinical significance of these changes warrants further investigation. Close monitoring of BP in hypertensive individuals post-vaccination is recommended.